New CoreValve Data Featured In TCT Late-Breaking Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Data on Medtronic’s CoreValve transcatheter aortic valve replacement device will headline this year’s Transcatheter Cardiovascular Therapeutics conference, joined by data on biodegradable drug-eluting stents, as well as drug-coated balloon results, in the late-breaking trial sessions.